Marker Therapeutics Awarded $13 1 Million Grant from the Cancer Prevention and Research Institute of Texas prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
Financialnewsmedia.com News Commentary
Share this article
Share this article
PALM BEACH, Fla., May 20, 2021 /PRNewswire/ Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of years. Revenues will increase but so will money flow into R&D efforts to treat this condition. Pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period. Furthermore, pancreatic cancer is ex
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
Marker continues to advance Phase 2 AML trial, recently dosing first patient
Company closed financing extending cash runway into Q1 2023
Company to host conference call and webcast today at 5:00 p.m. ET
News provided by
Share this article
Share this article
HOUSTON, May 12, 2021 /PRNewswire/ Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. We had a productive first quarter supported by our recently completed financing, strengthening our overall cash position and enabling continued growth and expansion of our Multi-TAA pipeline, said Peter L. Hoang, President & CEO of Marker Therapeutics. In add
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results
- Dosed first patient in the Company s Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia -
- Completed construction of new in-house cGMP manufacturing facility in Houston to supply MultiTAA-specific T cell products, including MT-401, for clinical activities and potential commercialization; facility expected to be fully operational in 1H 2021 -
News provided by
Share this article
Share this article
HOUSTON, March 9, 2021 /PRNewswire/ Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the fiscal year ended December 31, 2020.
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.